Biocon launches Hepatitis C drug
Biotechnology major Biocon has launched advanced novel therapy for the treatment of Hepatitis C.
New Delhi : Biotechnology major Biocon has launched advanced novel therapy for the treatment of Hepatitis C.
CIMIVIR-L, a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, will be made available to patients in India at a fraction of the global cost of the innovator brand, Biocon Ltd said in a statement.
The cost of a 12-week course of this combination therapy in the US is $94,500 (about Rs 63 lakh).
Biocon, President-Marketing, Ravi Limaye said the introduction of CIMIVIR-LTM will strengthen the company's current portfolio of virology products. "It furthers our commitment to offer affordable therapy for unmet patient needs in debilitating and life-threatening conditions," he added.
CIMIVIR-L is an equivalent of the innovator product commercialised by Gilead Sciences in the US. Biocon had entered into a licensing agreement last year with US-based Gilead to manufacture and commercialise its chronic Hepatitis-C blockbuster product range, Sofosbuvir and Sofosbuvir-Ledipasvir combination in India and in select emerging markets.
These territories account for more than 50 per cent of the global Hepatitis C prevalence.
The Drugs Controller General of India (DCGI) recently approved the sale of Sofosbuvir-Ledipasvir combination, which is being manufactured in India under a license from Gilead.
Interested in blogging for thehansindia.com? We will be happy to have you on board as a blogger.